Prevention of glucocorticoid-induced osteoporosis

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 6, 2009, Pages 997-1005

  Van Brussel, M S ^a   Bultink, I E M ^a   Lems, W F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone; Fracture; Glucocorticoids; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RISEDRONIC ACID; STEROID; STRONTIUM RANELATE; VITAMIN D; WNT PROTEIN; ZOLEDRONIC ACID;

BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE PREDISPOSITION; DIZZINESS; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP; HUMAN; INJECTION SITE REACTION; LIFESTYLE MODIFICATION; PATIENT COMPLIANCE; PHARMACOGENOMICS; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SPINE; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

EID: 67649598248     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902868225     Document Type: Review

References (69)

1. Manelli F, Giustina A. Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 2000;11:79-85 (Pubitemid 30164202)
2. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000 (Pubitemid 30350061)
3. Canalis E, Bilezikian JP, Angeli A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004;34:593-598 (Pubitemid 38393793)
4. Curtis JR, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 2007;5:14-21 (Pubitemid 46447927)
5. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006;79:129-137 (Pubitemid 44440440)
6. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-346 (Pubitemid 26334822)
7. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000;93:105-111 (Pubitemid 30098773)
8. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002;61:32-36 (Pubitemid 34074836)
9. Chiodini I, Carnevale V, Torlontano M, et al. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. J Clin Endocrinol Metab 1998;83:1863-1867 (Pubitemid 28496307)
10. Torlontano M, Chiodini I, Pileri M, et al. Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism. J Clin Endocrinol Metab 1999;84:2381-2385 (Pubitemid 30670866)
11. Tauchmanova L, Rossi R, Nuzzo V, et al. Bone loss determined by quantitative ultrasonometry correlates inversely with disease activity in patients with endogenous glucocorticoid excess due to adrenal mass. Eur J Endocrinol 2001;145:241-247 (Pubitemid 32825656)
12. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998;41:761-767 (Pubitemid 28225776)
13. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005;353:1711-1723 (Pubitemid 41464710)
14. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43 (Pubitemid 35346616)
15. Bartholome B, Spies CM, Gaber T, et al. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J 2004;18:70-80 (Pubitemid 38076467)
16. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007;357:905-916 (Pubitemid 47347324)
17. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-1066 (Pubitemid 29314048)
18. Quinn JM, Whitty GA, Byrne RJ, et al. The generation of highly enriched osteoclast-lineage cell populations. Bone 2002;30:164-170 (Pubitemid 34044315)
19. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319 (Pubitemid 27199902)
20. Roux S, Orcel P. Bone loss. Factors that regulate osteoclast differentiation: an update. Arthritis Res 2000;2:451-456
21. Jia D, O'Brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006;147:5592-5599 (Pubitemid 44833476)
22. Pereira RC, Delany AM, Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 2002;30:685-691 (Pubitemid 34467988)
23. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003;423:349-355 (Pubitemid 40852710)
24. Shoback D. Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab 2007;92:747-753 (Pubitemid 46465635)
25. Winkler DG, Sutherland MS, Ojala E, et al. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 2005;280:2498-2502 (Pubitemid 40189350)
26. Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep 2005;3:98-102
27. Ohnaka K, Tanabe M, Kawate H, et al. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005;329:177-181 (Pubitemid 40255437)
28. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-2494 (Pubitemid 38010074)
29. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-1316 (Pubitemid 28406817)
30. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004;145:1835-1841 (Pubitemid 38402392)
31. Masaki H, Miki T. Biochemical markers of bone in steroid (glucocorticoid)-induced osteoporosis (GIOP). Clin Calcium 2006;16:1823-1832
32. Lems WF, Van Veen GJ, Gerrits MI, et al. Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. Br J Rheumatol 1998;37:27-33 (Pubitemid 28371816)
33. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146:4577-4583 (Pubitemid 41446595)
34. Giustina A, Wehrenberg WB. The role of glucocorticoids in the regulation of growth hormone secretion mechanisms and clinical significance. Trends Endocrinol Metab 1992;3:306-311
35. Cooper MS. Sensitivity of bone to glucocorticoids. Clin Sci (Lond) 2004;107:111-123 (Pubitemid 39070927)
36. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-1328 (Pubitemid 47389469)
37. van Rossum EF, Voorhoeve PG, te Velde SJ, et al. The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults. J Clin Endocrinol Metab 2004;89:4004-4009 (Pubitemid 39071507)
38. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893-899 (Pubitemid 41103445)
39. De Vries F, Bracke M, Leufkens HG, et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007;56:208-214 (Pubitemid 46106193)
40. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-787 (Pubitemid 36336722)
41. van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-3229 (Pubitemid 37409336)
42. Luengo M, Picado C, Del Rio L, et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991;46:803-806
43. Goldstein MF, Fallon JJ Jr, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest 1999;116:1733-1749 (Pubitemid 30012719)
44. Goldring SR, Gravallese EM. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000;12:195-199 (Pubitemid 30238387)
45. Grainge MJ, Coupland CA, Cliffe SJ, et al. Cigarette smoking, alcohol and caffeine consumption, and bone mineral density in postmenopausal women. The Nottingham EPIC Study Group. Osteoporos Int 1998;8:355-363 (Pubitemid 28418270)
46. Korpelainen R, Korpelainen J, Heikkinen J, et al. Lifelong risk factors for osteoporosis and fractures in elderly women with low body mass index-a population-based study. Bone 2006;39:385-391 (Pubitemid 43851362)
47. Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007;21:109-122 (Pubitemid 46351951)
48. Compston J. US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences. Curr Rheumatol Rep 2004;6:66-69
49. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004;15:301-310 (Pubitemid 38543949)
50. Lips P. Relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 2007;22:1668-1671
51. van Staa TP, Geusens P, Pols HA, et al. A simple score for estimating the long-term risk of fracture in patients using oral. glucocorticoids QJM 2005;98:191-198
52. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-397
53. Available from: www.shef.ac.uk/NOGG
54. Saag KG, Gehlbach SH, Curtis JR, et al. Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 2006;33:1651-1657 (Pubitemid 44168842)
55. Duyvendak M, Naunton M, Atthobari J, et al. Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001-2005. Osteoporos Int 2007;18:1429-1433
56. Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-331 (Pubitemid 18104078)
57. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26:331-342 (Pubitemid 32989555)
58. Newman ED, Matzko CK, Olenginski TP, et al. Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006;17:1428-1434 (Pubitemid 44127331)
59. Lems WF. Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 2007;56:3518-3522 (Pubitemid 350100684)
60. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-299
61. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-285 (Pubitemid 30736856)
62. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-211 (Pubitemid 32113136)
63. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-2318 (Pubitemid 30333410)
64. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000;15:1006-1013
65. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001;69:242-247 (Pubitemid 33035397)
66. Roux C, Reid DM, Devogelaer JP, et al. Effect of zoledronic acid (Single 5-mg Infusion) on lumbar spine bone mineral density versus oral risedronate (5 mg/day) over 1 year in subgroups of patients receiving glucocorticoid therapy. J Bone Miner Res 2008;M363
67. Lems WF, Lodder MC, Lips P, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2006;17:716-723
68. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675-684 (Pubitemid 44244538)
69. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-2039 (Pubitemid 350106710)